KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects
Liu M, Townsend J. KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects. Lung Cancer 2025, 108749. DOI: 10.1016/j.lungcan.2025.108749.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune-checkpoint inhibitionTumor mutational burdenMutational burdenG12C mutationLung adenocarcinomaElevated tumor mutation burdenHigh tumor mutational burdenOncogenic potentialCell lung cancerKRAS G12C mutationImmunotherapy benefitICI outcomesSmoking historyLung cancerG12D mutationHazard ratioAllele-specific effectsKRASClinical trendsKRAS G12CResponse rateTumorG12CMutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply